Scholar Rock Narrows Q2 Loss, Eyes FDA Nod for Apitegromab by Sept 30
SRRK sits 94% above its 52-week low of $27.07.
Summary
Scholar Rock's Q2 net loss narrowed to $109.9M from a year ago, with operating expenses falling on lower R&D costs. The company ended the quarter with $492M in cash, bolstered by its ATM program. The key catalyst: potential FDA approval of apitegromab by September 30, 2026, with the company ready for an immediate U.S. launch. Engagement with the EMA on European approval is also underway. This follows a Q1 capital raise that extended the runway into 2027, and the upcoming FDA decision is the major binary event for the stock.
At the time of this announcement, SRRK was trading at $52.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $27.07 to $58.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.